Oric Pharmaceuticals, Inc.

ORIC Nasdaq SEC CIK 1796280
Follow Oric Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$48.1M −47.5% vs same quarter last year
EPS, diluted −$0.44 −33.3% vs same quarter last year
Operating cash flow −$42M −67.2% vs same quarter last year
Operating income −$51.6M −40.6% vs same quarter last year
Net income by quarter
−$36.3M
−$30M
−$36.4M
−$32.6M
−$30.5M
−$35.8M
−$41.5M
−$48.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$129.5M
FY24−$127.8M
FY23−$100.7M
FY22−$89.1M
FY21−$78.7M
FY20−$73.7M
FY19−$26.9M
FY18−$21.4M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$111.7M
FY24−$113.9M
FY23−$86.5M
FY22−$77.2M
FY21−$60.5M
FY20−$45.9M
FY19−$24.3M
FY18−$21.2M
FY17-